208 related articles for article (PubMed ID: 15493007)
21. ¹⁸F-fluorodeoxyglucose PET/computed tomography for primary brain tumors.
Segtnan EA; Hess S; Grupe P; Høilund-Carlsen PF
PET Clin; 2015 Jan; 10(1):59-73. PubMed ID: 25455880
[TBL] [Abstract][Full Text] [Related]
22. Assessment of treatment response using PET.
Basu S; Kumar R; Ranade R
PET Clin; 2015 Jan; 10(1):9-26. PubMed ID: 25455877
[TBL] [Abstract][Full Text] [Related]
23. Brain: positron emission tomography tracers beyond [¹⁸F]fluorodeoxyglucose.
Singhal T; Alavi A; Kim CK
PET Clin; 2014 Jul; 9(3):267-76. PubMed ID: 25030390
[TBL] [Abstract][Full Text] [Related]
24. The role of FDG PET in the management of lymphoma: what is the evidence base?
Kirby AM; Mikhaeel NG
Nucl Med Commun; 2007 May; 28(5):335-54. PubMed ID: 17414883
[TBL] [Abstract][Full Text] [Related]
25. The reproductive tract.
Jadvar H; Conti PS
Semin Nucl Med; 2004 Oct; 34(4):262-73. PubMed ID: 15493004
[TBL] [Abstract][Full Text] [Related]
26. The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective.
Lucignani G; Paganelli G; Bombardieri E
Nucl Med Commun; 2004 Jul; 25(7):651-6. PubMed ID: 15208491
[TBL] [Abstract][Full Text] [Related]
27. Autopsy as gold standard in FDG-PET studies in dementia.
Durand-Martel P; Tremblay D; Brodeur C; Paquet N
Can J Neurol Sci; 2010 May; 37(3):336-42. PubMed ID: 20481267
[TBL] [Abstract][Full Text] [Related]
28. Positron emission tomography imaging in dementia.
Herholz K; Carter SF; Jones M
Br J Radiol; 2007 Dec; 80 Spec No 2():S160-7. PubMed ID: 18445746
[TBL] [Abstract][Full Text] [Related]
29. Brain FDG PET and the diagnosis of dementia.
Shivamurthy VK; Tahari AK; Marcus C; Subramaniam RM
AJR Am J Roentgenol; 2015 Jan; 204(1):W76-85. PubMed ID: 25539279
[TBL] [Abstract][Full Text] [Related]
30. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging.
Silverman DH
J Nucl Med; 2004 Apr; 45(4):594-607. PubMed ID: 15073255
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the relationship between interictal electrical source imaging and PET hypometabolism.
Person C; Koessler L; Louis-Dorr V; Wolf D; Maillard L; Marie PY
Annu Int Conf IEEE Eng Med Biol Soc; 2010; 2010():3723-6. PubMed ID: 21096861
[TBL] [Abstract][Full Text] [Related]
32. Cardiac positron emission tomography imaging.
Machac J
Semin Nucl Med; 2005 Jan; 35(1):17-36. PubMed ID: 15645392
[TBL] [Abstract][Full Text] [Related]
33. Current Status of
Sarikaya I; Sarikaya A; Elgazzar AH
J Nucl Med Technol; 2018 Dec; 46(4):362-367. PubMed ID: 30076253
[No Abstract] [Full Text] [Related]
34. Brain fluorodeoxyglucose (FDG) PET in dementia.
Kato T; Inui Y; Nakamura A; Ito K
Ageing Res Rev; 2016 Sep; 30():73-84. PubMed ID: 26876244
[TBL] [Abstract][Full Text] [Related]
35. PET: too much of a good thing? Does the plethora of choices impact on patient management?
Divgi C; Pandit-Taskar N
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):398. PubMed ID: 15761778
[No Abstract] [Full Text] [Related]
36. Clinical PET/MR Imaging in Dementia and Neuro-Oncology.
Henriksen OM; Marner L; Law I
PET Clin; 2016 Oct; 11(4):441-52. PubMed ID: 27593248
[TBL] [Abstract][Full Text] [Related]
37. A Cochrane review on brain [¹⁸F]FDG PET in dementia: limitations and future perspectives.
Morbelli S; Garibotto V; Van De Giessen E; Arbizu J; Chételat G; Drezgza A; Hesse S; Lammertsma AA; Law I; Pappata' S; Payoux P; Pagani M;
Eur J Nucl Med Mol Imaging; 2015 Sep; 42(10):1487-91. PubMed ID: 26067090
[No Abstract] [Full Text] [Related]
38. Clinical use of positron emission tomography in the management of cutaneous melanoma.
Friedman KP; Wahl RL
Semin Nucl Med; 2004 Oct; 34(4):242-53. PubMed ID: 15493002
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic Performance of Positron Emission Tomography for the Presurgical Evaluation of Patients with Non-lesional Intractable Partial Epilepsy: Comparison among 18F-FDG, 11C-Flumazenil, and 11C-Flumazenil Binding Potential Imaging Using Statistical Imaging Analysis.
Komoto D; Iida K; Higaki T; Kaichi Y; Takauchi K; Arihiro K; Kakita A; Hirokawa Y; Awai K
Hiroshima J Med Sci; 2015 Dec; 64(4):51-7. PubMed ID: 26964154
[TBL] [Abstract][Full Text] [Related]
40. Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations.
Krak NC; Hoekstra OS; Lammertsma AA
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S103-11. PubMed ID: 15103507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
